argenx (NASDAQ:ARGX - Get Free Report) announced its earnings results on Thursday. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $1.29, Zacks reports. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The firm had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter last year, the business earned ($1.25) earnings per share.
argenx Stock Performance
Shares of NASDAQ ARGX traded up $9.28 during midday trading on Friday, hitting $595.58. The company's stock had a trading volume of 449,545 shares, compared to its average volume of 309,272. argenx has a 1-year low of $327.73 and a 1-year high of $610.73. The firm's fifty day moving average price is $537.88 and its 200-day moving average price is $464.29. The firm has a market cap of $35.61 billion, a P/E ratio of -680.98 and a beta of 0.63.
Wall Street Analyst Weigh In
ARGX has been the topic of a number of analyst reports. Barclays upgraded shares of argenx from an "equal weight" rating to an "overweight" rating in a research report on Tuesday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of argenx from $500.00 to $640.00 and gave the company an "overweight" rating in a report on Friday, August 23rd. HC Wainwright lifted their price target on shares of argenx from $533.00 to $617.00 and gave the company a "buy" rating in a report on Friday. Raymond James reiterated a "strong-buy" rating and issued a $605.00 price target on shares of argenx in a report on Thursday, October 10th. Finally, Piper Sandler lifted their target price on shares of argenx from $553.00 to $620.00 and gave the company an "overweight" rating in a report on Friday. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, argenx has a consensus rating of "Moderate Buy" and a consensus price target of $596.78.
Get Our Latest Research Report on ARGX
About argenx
(
Get Free Report)
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Featured Articles
Before you consider argenx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenx wasn't on the list.
While argenx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
